New York, New York (PRWEB) June 19, 2013
As Januvia lawsuit claims involving pancreatitis and pancreatic cancer continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) recently held a meeting to discuss the safety of Januvia and other diabetes drugs known as incretin mimetics. According to a June 12th report from Bloomberg.com, the FDA may seek additional data from the makers of Januvia and similar drugs, following a recent study that indicated the medications could increase risks for pancreatic cancer. One of the options being considered by the agency is a large clinical trial designed to show patterns of adverse events. *
“In light of the possible link between Januvia and pancreatic cancer, we certainly hope that the FDA will order more studies of these drugs,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit evaluations to patients who took the medication and were diagnosed with pancreatic cancer or pancreatitis.
Incretin mimetics like Januvia help regulate blood sugar by stimulating insulin production by the pancreas. In 2009, information was added to the drug’s label regarding a potential risk for Januvia pancreatitis, after the FDA became aware of 88 post-marketing cases of acute pancreatitis that occurred in patients taking the drug.** In 2011, a study published in the journal Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis by as much as six-fold. The same study found a possible link between Januvia and pancreatic cancer.***
The FDA’s recent meeting was prompted by data from an unpublished study that drugs like Januvia could cause precancerous changes in the cell of the pancreas, Bloomberg.com said. Just prior to the meeting, the American Diabetes Association called for an independent review of all incretin mimetics to provide clarity to patients and health care providers in light of the recent controversy.****
Court documents indicate that Januvia lawsuits filed on behalf of patients who used the drug and developed pancreatic cancer and pancreatitis are already mounting in courts throughout the country. On July 25, 2013, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will meet to discuss whether or not a multidistrict litigation should be established for all federally-filed claims involving incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)
Alleged victims of Januvia pancreatitis or pancreatic cancer may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.
**fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm; September 25, 2009
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10850018.htm.
Copyright©2012 Vocus, Inc.
All rights reserved